A number of research firms have changed their ratings and price targets for Avita Medical (NASDAQ: RCEL):
- 11/14/2026 – Avita Medical was upgraded by Wall Street Zen from “hold” to “buy”.
- 11/12/2026 – Avita Medical had its price target raised by TD Cowen from $20.00 to $22.00. They now have a “buy” rating on the stock.
- 11/6/2026 – Avita Medical had its price target raised by Lake Street Capital from $12.00 to $20.00. They now have a “buy” rating on the stock.
- 11/6/2026 – Avita Medical had its price target raised by BTIG Research from $15.00 to $21.00. They now have a “buy” rating on the stock.
- 11/3/2026 – Avita Medical had its “buy” rating reaffirmed by TD Cowen.
- 10/12/2026 – Avita Medical had its price target raised by BTIG Research from $11.00 to $15.00. They now have a “buy” rating on the stock.
- 9/21/2026 – Avita Medical had its “sell (e+)” rating reaffirmed by Weiss Ratings.
Avita Medical Stock Performance
RCEL opened at $15.22 on Tuesday. Avita Medical Inc. has a one year low of $3.22 and a one year high of $18.43. The stock’s fifty day moving average is $13.48 and its 200-day moving average is $7.22. The company has a market capitalization of $478.21 million, a PE ratio of -12.90 and a beta of 2.03.
Avita Medical (NASDAQ:RCEL – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. The firm had revenue of $26.11 million for the quarter, compared to the consensus estimate of $22.35 million. On average, equities research analysts forecast that Avita Medical Inc. will post -0.94 EPS for the current fiscal year.
AVITA Medical is a regenerative medicine company focused on treatments for skin restoration. Its flagship technology, the RECELL System, enables clinicians to use a small sample of a patient’s healthy skin to prepare a suspension of skin cells for application to wounds. The company’s RECELL products are used in the treatment of burns and certain other skin injuries, including full-thickness skin defects. The approach is intended to support wound coverage while reducing the amount of donor skin needed compared with conventional skin-grafting procedures.
Featured Articles
- Five stocks we like better than Avita Medical
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Avita Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avita Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.
